

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

This announcement is made by MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

It has come to the attention of the Company that there has been significant fluctuation on the share price of the Company recently. The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby informs the shareholders of the Company and potential investors that the Group’s major businesses maintain steady growth, and the Director(s) and the management of the Company are confident about the development of the Group. Since the beginning of year 2023, the Group and its associated companies has had 33 products that have obtained Class III registration certificates or important approvals on registration changes by National Medical Products Administration (“**NMPA**”). Recent approvals on registration changes and initial registration include but not limited to registration change for Toumai[®] multidisciplinary application and the Columbus 3D EP Navigation System V4, as well as initial registration approved for IceMagic[®] Cryoablation Product Series, SkyWalker[™] THA, Tigertriever[®] Revascularization Device, WAVE-track[™] Intracranial Aspiration Catheter, AccuSniper[™] Double-layer Balloon Catheter, Interline[™] Guide Catheter, etc.. In the overseas market, the Group and its associated companies have had 15 products that have obtained U.S. Food and Drug Administration (“**FDA**”) approvals and 10 products that have obtained CE mark since the beginning of year 2023, including major products such as Alizea[™] and Celea[™] implantable Bluetooth pacemakers together with their accessory products, DFVision[®] 3D Electronic Laparoscope, TrueForce[®] Single-use strain gauge Magnetic-locating Ablation catheter as well as AncherV[™]Anchor Balloon.

In addition, based on the current progress in product development and registration, the Group’s key products that are expected to obtain approval for launch around year 2024 include Rotational Atherectomy System, Coronary Shock Wave Balloon Catheter System, ENO[™] MRI Compatible Pacemaker, and third-generation TAVI Product, which are expected to become new growth engines. The Group will continue to efficiently advance the expansion and promotion of launched products in domestic and overseas markets, fully unleash the platform synergies through the high-value global

product layout, and drive the continuous improvement of the value of the Company while providing more high-quality medical solutions for patients.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 11 December 2023

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun, Dr. Qiyi Luo and Mr. Bo Peng; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*